{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:20:18Z","timestamp":1783455618072,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:p>\n                    Hyperbaric oxygen therapy (HBOT) is increasingly utilized as an adjunctive treatment in oncology; however, data on its hematological safety (particularly when combined with chemotherapy or traditional herbal therapies) remain limited. We retrospectively analyzed electronic medical records of adults with malignant neoplasms who received HBOT at Cha Ilsan Medical Center from July 1, 2022 to December 31, 2024. Safety was assessed via treatment-emergent adverse events graded by Common Terminology Criteria for Adverse Events and pre\u2013post comparisons of 37 laboratory parameters. Subgroup analyses were stratified by chemotherapy and herbal therapy (traditional Korean medicine) exposure. Covariate-adjusted linear regression models were used to identify independent predictors of laboratory changes after false-discovery-rate correction. Among 259 patients undergoing 2692 HBOT sessions, 2 mild treatment-emergent adverse events occurred (0.07%); no serious or life-threatening events were observed. In 207 patients with paired laboratories, most hematologic and biochemical parameters were stable. Platelet count declined modestly (\u221216\u2005\u00d7\u200510\n                    <jats:sup>3<\/jats:sup>\n                    \u00b5L\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; false-discovery-rate\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and plateletcrit decreased (\u22120.01%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), with cohort means remaining within reference intervals. In the paired-laboratory cohort, chemotherapy exposure was 108 vs 99 unexposed, and herbal therapy (traditional Korean medicine) exposure was 132 vs 75 unexposed; exposures were not mutually exclusive. Subgroup analyses showed no clinically meaningful hematologic differences between exposed and unexposed groups. In multivariable linear models, chemotherapy was independently associated with lower white blood cell and neutrophil counts, and herbal therapy with a minor reduction in eosinophils; neither therapy was associated with platelet changes. Low-pressure HBOT demonstrates a favorable hematological safety profile in cancer patients, even when administered alongside chemotherapy or herbal therapies. These findings support the safe integration of HBOT into multimodal cancer care, although prospective multicenter trials are warranted to confirm long-term safety.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044893","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:00:55Z","timestamp":1760331655000},"page":"e44893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hematological safety of hyperbaric oxygen therapy in oncology: Stratified analysis by chemotherapy and herbal medicine use"],"prefix":"10.1097","volume":"104","author":[{"given":"Myeongseog","family":"Woo","sequence":"first","affiliation":[{"name":"Department of Bioconvergence and Engineering, Graduate School, Dankook University, Yongin, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Integrative Cancer Center, Cha Ilsan Medical Center, Goyang-si, Gyeonggi-do, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Han","family":"Hyun","sequence":"additional","affiliation":[{"name":"Integrative Cancer Center, Cha Ilsan Medical Center, Goyang-si, Gyeonggi-do, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-9555","authenticated-orcid":false,"given":"Sanghun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Bioconvergence and Engineering, Graduate School, Dankook University, Yongin, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260113","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/bmj.317.7166.1140","article-title":"Hyperbaric oxygen therapy.","volume":"317","author":"Leach","year":"1998","journal-title":"BMJ"},{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/08850666241313136","article-title":"A review of emerging evidence and clinical applications of hyperbaric oxygen therapy.","volume":"40","author":"Patel","year":"2025","journal-title":"J Intensive Care Med"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1056\/NEJM199606203342506","article-title":"Hyperbaric-oxygen therapy.","volume":"334","author":"Tibbles","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/qjmed\/hch074","article-title":"Hyperbaric oxygen: its uses, mechanisms of action and outcomes.","volume":"97","author":"Gill","year":"2004","journal-title":"QJM"},{"key":"R5-20260113","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/medicina57090864","article-title":"A general overview on the hyperbaric oxygen therapy: applications, mechanisms and translational opportunities.","volume":"57","author":"Ortega","year":"2021","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/amj-20-178","article-title":"Narrative review of hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis.","volume":"7","author":"Dieu","year":"2022","journal-title":"AME Med J"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"e37493","DOI":"10.1097\/MD.0000000000037493","article-title":"The effect of hyperbaric oxygen therapy on hematological indices and biochemical parameters in patients with diabetic foot.","volume":"103","author":"Ercan","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R8-20260113","doi-asserted-by":"crossref","first-page":"131S","DOI":"10.1097\/PRS.0b013e3181fbe2bf","article-title":"Hyperbaric oxygen: its mechanisms and efficacy.","volume":"127","author":"Thom","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/2045-9912.310057","article-title":"Therapeutic effects of hyperbaric oxygen: integrated review.","volume":"11","author":"Sen","year":"2021","journal-title":"Med Gas Res"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"e70109","DOI":"10.1002\/cnr2.70109","article-title":"Short- and long-term efficacy of hyperbaric oxygen therapy in irradiated breast cancer patients with long-standing lymphedema: a prospective case series.","volume":"8","author":"Chitapanarux","year":"2025","journal-title":"Cancer Reports"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1515\/oncologie-2024-0263","article-title":"Anti-cancer effects of hyperbaric oxygen therapy in mice: a meta-analysis.","volume":"26","author":"Klement","year":"2024","journal-title":"Oncologie"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11523-012-0233-x","article-title":"Hyperbaric oxygen therapy and cancer \u2013 a review.","volume":"7","author":"Moen","year":"2012","journal-title":"Targeted Oncology"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1742-4801.2005.00079.x","article-title":"Radiotherapy and wound healing.","volume":"2","author":"Dormand","year":"2005","journal-title":"Int Wound J"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"101694","DOI":"10.1016\/j.gore.2025.101694","article-title":"Hyperbaric oxygen therapy: a practical guide for gynecologic oncologists.","volume":"58","author":"Foy","year":"2025","journal-title":"Gynecologic Oncol Reports"},{"key":"R15-20260113","first-page":"1241","article-title":"Hyperbaric oxygen therapy accelerates vascularization in keratinized oral mucosal surgical flaps.","volume":"36","author":"Helmers","year":"2014","journal-title":"Head Neck"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"1200619","DOI":"10.3389\/fonc.2023.1200619","article-title":"Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment.","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"R17-20260113","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1038\/s41598-021-91454-2","article-title":"Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer.","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"key":"R18-20260113","first-page":"CD005005","article-title":"Hyperbaric oxygen therapy for late radiation tissue injury.","volume":"8","author":"Lin","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12032-016-0814-0","article-title":"Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours.","volume":"33","author":"St\u0119pie\u0144","year":"2016","journal-title":"Med Oncol"},{"key":"R20-20260113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/02656730802610357","article-title":"Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results.","volume":"25","author":"Ohguri","year":"2009","journal-title":"Int J Hyperthermia"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.21037\/tcr.2018.04.16","article-title":"The efficacy and tolerance of high pressure oxygen combined with chemotherapy in postoperative patients with advanced gastric cancer.","volume":"7","author":"Qian","year":"2018","journal-title":"Transl Cancer Res"},{"key":"R22-20260113","doi-asserted-by":"crossref","first-page":"1254322","DOI":"10.3389\/fonc.2023.1254322","article-title":"Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma \u2013 a narrative review.","volume":"13","author":"Alpuim Costa","year":"2023","journal-title":"Front Oncol"},{"key":"R23-20260113","doi-asserted-by":"crossref","first-page":"764002","DOI":"10.3389\/fvets.2021.764002","article-title":"Common uses and adverse effects of hyperbaric oxygen therapy in a cohort of small animal patients: a retrospective analysis of 2,792 treatment sessions.","volume":"8","author":"Montalbano","year":"2021","journal-title":"Front Veterinary Sci"},{"key":"R24-20260113","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/apt.12753","article-title":"Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease.","volume":"39","author":"Dulai","year":"2014","journal-title":"Alimentary Pharmacol Therap"},{"key":"R25-20260113","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/wound.2016.0718","article-title":"Hyperbaric oxygen therapy: side effects defined and quantified.","volume":"6","author":"Heyboer","year":"2017","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R26-20260113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.ASW.0000508712.86959.c9","article-title":"A retrospective analysis of adverse events in hyperbaric oxygen therapy (2012-2015): lessons learned from 1.5 million treatments.","volume":"30","author":"Jokinen-Gordon","year":"2017","journal-title":"Adv Skin Wound Care"},{"key":"R27-20260113","doi-asserted-by":"crossref","first-page":"1160774","DOI":"10.3389\/fmed.2023.1160774","article-title":"Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis.","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med"},{"key":"R28-20260113","doi-asserted-by":"crossref","first-page":"e062322","DOI":"10.1136\/bmjopen-2022-062322","article-title":"Efficacy and safety of hyperbaric oxygen therapy for fibromyalgia: a systematic review and meta-analysis.","volume":"13","author":"Chen","year":"2023","journal-title":"BMJ Open"},{"key":"R29-20260113","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41598-021-81886-1","article-title":"Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials.","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci Rep"},{"key":"R30-20260113","doi-asserted-by":"crossref","first-page":"357","DOI":"10.22462\/7.8.2017.8","article-title":"Effect of hyperbaric oxygen therapy on complete blood count.","volume":"44","author":"Gunes","year":"2017","journal-title":"Undersea Hyperb Med"},{"key":"R31-20260113","doi-asserted-by":"crossref","first-page":"1485676","DOI":"10.3389\/fmed.2025.1485676","article-title":"Differences in the count of blood cells pre-and post-chemotherapy in patients with cancer: a retrospective study (2022).","volume":"12","author":"Kassie","year":"2025","journal-title":"Front Med"},{"key":"R32-20260113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/medicina61030385","article-title":"Hyperbaric oxygen therapy for managing cancer treatment complications: a safety evaluation.","volume":"61","author":"Canarslan Demir","year":"2025","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"R33-20260113","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.phrs.2010.04.005","article-title":"The activity of medicinal plants and secondary metabolites on eosinophilic inflammation.","volume":"62","author":"Rogerio","year":"2010","journal-title":"Pharmacol Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:02:03Z","timestamp":1768334523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":33,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044893","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}